Fosaprepitant (STUDY DRUG)
Disclaimer: Official controlled document is the CHEO online copy. It is the responsibility of user to ensure that any paper copy version is the same as the online version before use.
AHFS 56:22.92 Miscellaneous Antiemetics
- Prevention of acute and delayed nausea and vomiting due to highly emetogenic cancer chemotherapy
Reconstitution and Stability:
||0.9% SODIUM CHLORIDE for INJECTION
|| 5 mL
|| 30 mg/mL
- Add saline towards vial wall to prevent foaming
- Swirl gently to dissolve. DO NOT SHAKE
- Further dilute with 0.9% NaCl to prepare a 1 mg/mL solution
- Solutions Compatible: 0.9% NaCl
Incompatible: solutions containing divalent cations (i.e. Ca+2, Mg+2) including Lactated Ringer's solution
(For approved routes of administration by nursing personnel, refer to Policy for the Administration of Intravenous Medications.)
|IV Intermittent Infusion
Usual dilution: 1 mg/mL
Infusion time: 1 hour
|IV Continuous Infusion
(For neonatal dosages, refer to Neonatal IV Drug Manual.)
- as per protocol: 3 mg/kg
- 150 mg
Potential hazards of parenteral administration:
- Hypersensitivity reactions including flushing, erythema, and dyspnea have occurred during infusion of fosaprepitant. Discontinue infusion and administer appropriate therapy
- Irritation at the injection site
- Fosaprepitant is an inhibitor of CYP3A4 enzyme so there is a potential for many drug interactions
- Fosaprepitant cannot be removed by hemodialysis
- Reported side effects: asthenia, fatigue, constipation, diarrhea, nausea, decreased appetite, headache, dizziness and hiccups
The information contained on this website is provided for informational purposes only, as a guide to assist physicians, nurses and other healthcare providers in deciding on the appropriate care required for a particular patient. At all times, physicians, nurses and other healthcare providers must exercise their independent clinical judgment, based on their knowledge, training and experience, taking into account the specific facts and circumstances of each patient, when deciding on the appropriate course of investigation and/or treatment to recommend in a particular clinical situation.
CHEO has made every effort to ensure that the information contained on this website is as current and accurate as possible. However, changes can occur due to ongoing research and the constant influx of new information. Where possible, hospitals and healthcare practitioners should verify the information before acting on it.
Reliance on any information in this website is at the user's own risk. CHEO is not responsible or liable for any harm, loss or other consequences from the use or misuse of the information on this website.